RESUMEN
The emergence of mobile head-mounted displays with robust "inside-out" markerless tracking and video-passthrough permits the creation of novel mixed reality (MR) experiences in which architectural spaces of arbitrary size can be transformed into immersive multi-user visualisation arenas. Here we outline ViewR, an open-source framework for rapidly constructing and deploying architectural-scale multi-user MR experiences. ViewR includes tools for rapid alignment of real and virtual worlds, tracking loss detection and recovery, user trajectory visualisation and world state synchronisation between users with persistence across sessions. ViewR also provides control over the blending of the real and the virtual, specification of site-specific blending zones, and video-passthrough avatars, allowing users to see and interact with one another directly. Using ViewR, we explore the transformation of large architectural structures into immersive arenas by creating a range of experiences in various locations, with a particular focus on architectural affordances such as mezzanines, stairs, gangways and elevators. Our tests reveal that ViewR allows for experiences that would not be possible with pure virtual reality, and indicate that, with certain strategies for recovering from tracking errors, it is possible to construct large scale multi-user MR experiences using contemporary consumer virtual reality head-mounted displays.
RESUMEN
The aim of this study was to assess the efficacy of lipophilic beta-blockers in preventing recurrent neurocardiogenic syncope and the value of head-up tilt test (HUT) in predicting response to therapy. The efficacy of beta-blockers in recurrent syncope is controversial. The value of HUT in predicting efficacy of therapy has not been investigated. Fifty-six patients (44+/-18 years, 36 women) with recurrent syncope (> 1 event in the last 6 months) of suspected neurocardiogenic origin were included in the study. Independent of the response to HUT, patients were randomized to receive metoprolol or propanolol at the maximal tolerated dose (28 patients, group A, 86+/-23 vs 98+/-29 mg/d) or no pharmacological therapy (28 patients, group B). The primary endpoint was the first recurrence of syncope. During the 1-year of follow-up, 20 patients of group A and 8 of group B had no recurrence. In group A, of 20 patients without recurrences 12 had a positive and 8 a negative HUT result while of 8 patients with recurrences 5 had a positive and 3 a negative response to HUT. In the group B, of 20 patients with recurrences 10 had a positive and 10 a negative HUT result while of 8 patients without recurrences 4 had a positive and 4 a negative response to HUT. In a multivariate Cox-regression analysis, medical therapy was the only independent factor for predicting recurrence of syncope (P = 0.004); HUT had no influence in this regard (P = 0.773). In conclusion, lipophilic beta-blockers appear efficacious in preventing recurrent syncope of suspected neurocardiogenic origin. The efficacy of therapy seems to be not predicted by HUT.